BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for betamethasone acetate; betamethasone sodium phosphate and what is the scope of freedom to operate?
Betamethasone acetate; betamethasone sodium phosphate
is the generic ingredient in two branded drugs marketed by Am Regent, Hikma, and Organon, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.Five suppliers are listed for this compound.
Summary for BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 3 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 5 |
Clinical Trials: | 2 |
DailyMed Link: | BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE at DailyMed |
Recent Clinical Trials for BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tel-Aviv Sourasky Medical Center | N/A |
University of Kentucky | Early Phase 1 |
Edward Kasaraskis | Early Phase 1 |
See all BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE clinical trials
Pharmacology for BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Am Regent | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 090747-001 | Jul 31, 2009 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Organon | CELESTONE SOLUSPAN | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 014602-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hikma | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 077838-001 | Jan 17, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Organon | CELESTONE SOLUSPAN | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 014602-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.